Drug Trial Radar · NCT01438112
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Last checked: Nov 20, 2026Latest source record: Apr 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
22
Actual
Start
Mar 2014
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- CG Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of the immune system for local cancer cell death as well as destroying those tumor cells that may have travelled to regional lymph nodes or distant organs.
Conditions
- Transitional Cell Carcinoma
- Bladder Cancer
- Carcinoma in Situ
- Carcinoma in Situ Concurrent With Papillary Tumors
Interventions
CG0070 Adenovirus VectorBiological
CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
Control Arm: Quadruple ChoiceOther
Quadruple Choice Treatment Options: (same as listed above)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response Proportion (CR)Time frame: 9 months (Phase II)
- Durable Complete Response Proportion (DCR)Time frame: 15 months (Phase III)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
BCG Oncology
Phoenix, Arizona
University of California, San Diego- Moores Cancer Center
La Jolla, California
UCLA Institute of Urological Oncology
Los Angeles, California
University of California, Davis- Cancer Center
Sacramento, California
University of Chicago, Department of Surgery, Section of Urology
Chicago, Illinois
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Vanderbilt University Medical Center Department of Urologic Surgery
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.